| DB ID | MyCo_2426 |
| Title | Performance of galactomannan testing from endotracheal aspirate to guide bronchoalveolar lavage in the diagnosis of invasive aspergillosis |
| Year | 2023 |
| PMID | 36738420 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This retrospective study was reviewed and approved by the ethics committee of the University Hospital of LMU Munich (Ethikkommission bei der Medizinischen Fakultät der LMU München; no. 17-565; 20/16/06) and conducted in accordance with the Declara-tion of Helsinki. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | The analysis was performed at the Max von Pettenkofer- Institute for Hygiene and Medical Microbiology. All samples were obtained in the University Hospital of Ludwig- Maximilians-University, a 2000-bed tertiary care center in Munich, Germany. The first set consisted of 140 consecutive BAL/ETA pairs obtained from 133 patients, with a maximum time difference of one day between ETA and BAL sampling. To strengthen the significance of our analysis, an additional second BAL/ETA set (n = 38) was analyzed. |
| Cohort No. | 171 |
| Age Group | 57 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is an invasive fungal infection caused by Aspergillus species and poses a major threat to immunocompromised individuals. Diagnosis is challenging, owing to the pathogen’s ubiquitous nature and non-specific clinical presentation, and is therefore based on a combina-tion of clinical, microbiological, and radiological findings. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Platelia Aspergillus EIA; Bio-Rad, Marnes la Coquette, France) |
| Assay Data | None |
| Validation Techniques used | FDA Approved -Platelia Aspergillus Ag ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
